CTI Biopharma Corp reports results for the quarter ended in September - Earnings Summary

CTI Biopharma

07/11/2022 22:03

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss
of 13 cents​​ per share for the quarter ended in September. The
mean expectation of nine analysts for the quarter was for a loss
of 16 cents per share.
    * Revenue was $18.24 million​; analysts expected $17.17
million. 
    * CTI Biopharma Corp's reported EPS for the quarter was a
loss
of 13 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.6%
in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * CTI Biopharma Corp shares had fallen by 8.2% this
quarter and
gained 115.3% so far this year.
    * The company reported a quarterly loss of $15.71 million.
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.16          -0.13          Beat
 Jun. 30 2022      -0.20          -0.21          Missed
 Mar. 31 2022      -0.41          -0.37          Beat
 Dec. 31 2021      -0.28          -0.38          Missed